<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="112765">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02083666</url>
  </required_header>
  <id_info>
    <org_study_id>SOBI002-001</org_study_id>
    <nct_id>NCT02083666</nct_id>
  </id_info>
  <brief_title>Safety and Tolerability of SOBI002 in Healthy Volunteers Following Single and Repeated Administration</brief_title>
  <official_title>Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of SOBI002 Following Subcutaneous and Intravenous Administration. A Double-blind, Placebo-controlled, Randomized Within Dose Cohort, Single and Repeated Dose-escalation Study in Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Swedish Orphan Biovitrum</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Richmond Pharmaceuticals Ltd.</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Swedish Orphan Biovitrum</source>
  <oversight_info>
    <authority>United Kingdom: Medicines and Healthcare Products Regulatory Agency</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main purpose of this study is to assess the safety and tolerability of SOBI002 in
      healthy volunteers following single and repeated administration.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a double-blind, placebo-controlled, randomized within dose cohort single and
      repeated dose study with sequential dose escalation.

      Eligible volunteers will be divided into dose cohorts and for each cohort, a new panel of 8
      volunteers will be randomized to receive either SOBI002 (n=6) or placebo (n=2). SOBI002 will
      either be administered subcutaneously or intravenously.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>December 2013</start_date>
  <completion_date type="Anticipated">January 2015</completion_date>
  <primary_completion_date type="Anticipated">January 2015</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>To assess the safety and tolerability of SOBI002 in healthy volunteers following single and repeated adminstration</measure>
    <time_frame>Up to 13 weeks</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Safety will be evaluated by assessing all Adverse Events, vital signs, 12-lead ECGs, urine samples for determination of urinalysis variables and blood samples for determination of hematology, biochemistry and coagulation variables.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Assessment of pharmacokinetics of SOBI002 through analysis of serum samples</measure>
    <time_frame>Up to 13 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of pharmacodynamics by assessing the inhibition of SOBI002 on hemolytic activity</measure>
    <time_frame>Up to 13 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of the immungenicity of SOBI002 by measuring the occurence of anti-drug antibodies</measure>
    <time_frame>Up to 13 weeks</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>SOBI002</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single and repeated administration of different doses of test product</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Matching reference product</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SOBI002</intervention_name>
    <description>Test Product</description>
    <arm_group_label>SOBI002</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Reference product</description>
    <arm_group_label>placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Females of non-childbearing potential or males

          -  18 to 45 years of age

          -  Judged by the Principal Investigator to be healthy on the basis of medical history
             and a pre-study physical examination including 12-lead electrocardiogram (ECG),
             24-hour Holter ECG, vital signs and blood and urine laboratory assessments.

        Exclusion Criteria:

          -  Females of childbearing potential

          -  Clinically significant disease

          -  Clinically significant abnormal laboratory, ECG, vital signs or other safety findings
             as determined by medical history, physical examination or other evaluations conducted
             at screening or on admission.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hans Olivecrona, MD</last_name>
    <role>Study Director</role>
    <affiliation>Swedish Orphan Biovitrum AB (publ)</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Karin Gr√ºnbaum, MSc Pharm</last_name>
    <phone>+46760011502</phone>
    <email>karin.grunbaum@sobi.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Elin Rosendahl, MSc Pharm</last_name>
    <phone>+4686973142</phone>
    <email>elin.rosendahl@sobi.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Richmond Pharmacology Ltd.</name>
      <address>
        <city>London</city>
        <state>St George's University of London</state>
        <zip>SW17 0RE</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ulrike Lorche, MD FRCA FFPM</last_name>
      <phone>+442086645200</phone>
      <email>u.lorch@richmondpharmacology.com</email>
    </contact>
    <contact_backup>
      <last_name>Linh Schram</last_name>
      <phone>+442086645200</phone>
      <email>l.schram@richmondpharmacology.com</email>
    </contact_backup>
    <investigator>
      <last_name>Ulrike Lorch, MD FRCA FFPM</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>March 2014</verification_date>
  <lastchanged_date>March 10, 2014</lastchanged_date>
  <firstreceived_date>January 15, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Phase I</keyword>
  <keyword>Dose cohorts</keyword>
  <keyword>Escalating dose</keyword>
  <keyword>Single dose</keyword>
  <keyword>Multiple dose</keyword>
  <keyword>Safety</keyword>
  <keyword>Tolerability</keyword>
  <keyword>Pharmacokinetics</keyword>
  <keyword>Pharmacodynamics</keyword>
  <keyword>volunteers</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
